NxStageÃ‚® Supports Initiative by Patient Advocacy Groups to Educate Policymakers about the Benefits of Frequent Home Hemodialysis
LAWRENCE, Mass., May 9, 2011 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today expressed its support for an initiative by three patient advocacy groups to educate U.S. Congressional policymakers and their advisors about the benefits of home dialysis, including frequent home hemodialysis.
On Tuesday, May 10th, delegations from the National Kidney Foundation, Friends of the Congressional Kidney Caucus and NxStageUsers Group will host a special briefing for Congresspersons and their staff, where they will present important new developments and studies indicating marked improvement in kidney patient health particularly through advances in frequent home hemodialysis. NxStageUsers is an independent patient group that has no organizational or fiduciary relationships with NxStage Medical, Inc.
"NxStage is committed to ensuring that every dialysis patient is informed about and has equal access to all appropriate treatment options, including more frequent home hemodialysis," said Jeffrey H. Burbank, Chief Executive Officer of NxStage Medical, Inc. "The growing body of independent clinical data documenting the lower mortality, improved quality of life, and other significant clinical benefits made possible uniquely with more frequent hemodialysis provides overwhelming evidence in support of this therapy. Access to more frequent hemodialysis at home for all patients who might benefit should be a priority for providers, payors and policymakers."
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the trea